Longs will be super wealthy if manufacturing capacity ever becomes even nearly an issue. Realistically, I believe, it's very doubtful if the initial artisan capacity is stressed at all in the first year after UK approval. It's not like instantly, bada bing, and every GMB patient in the UK is going to be getting Dc-Vax-L. I have zero experience with this, but that's my common-sense appraisal. Even at double to triple that capacity, it will take additional geographic approvals to increase to that many GBM patients. IMO the most likely scenario to push to any practical capacity limit will be after Direct tests very well and then gets approved, if it does. Maybe 4 years out? Certainly no less than 3 imo.
Market Data 
Markets 
AI
